Previous 10 | Next 10 |
Co-Diagnostics (NASDAQ: CODX) was a penny stock at the beginning of 2020, with its shares trading hands for $0.90 at the beginning of the year. By December this biotech stock was up to $9.30. What caused this fantastic run-up, and is there any more gas in the tank? Motley Fool contr...
Are These Top Biotech Stocks On Your Watchlist? 3 In Focus During a pandemic, the healthcare industry would normally be in the spotlight. Because of this, we have seen biotech stocks become the top performers on the stock market . Throughout 2020, many biotech companies shif...
Co-Diagnostics Completes FDA EUA Submission for Extraction-Free Saliva COVID-19 Test The Company's Logix Smart™ SARS-CoV-2 DS (Direct Saliva) test is designed to reduce sample processing time and cost by eliminating the extraction process PR Newswire SALT LA...
COVID-19 shocked the stock market in 2020, causing massive disruptions in the world economy and killing a lot of innocent people. While major healthcare companies responded to this threat, the stocks that soared were tiny biotech companies, names like Novavax (NASDAQ: NVAX) , Vaxa...
This article looks at the 17 companies listed on U.S. exchanges that had a higher total return than high-flying Tesla in 2020. The stocks tended to be microcap to small cap stocks in sectors that piqued investor interest in 2020. These companies on average are unprofitable and tra...
There's been a lot of hype around recent IPO Snowflake (NYSE: SNOW) , and much of that is deserved. The cloud-data company has been consistently growing sales ever since its founding in 2012, logging 115% year-over-year revenue growth in the latest quarter. Contrast Snowflak...
New York, NY (1/13/2021) – As the most at-risk people begin to receive COVID-19 vaccinations, we are all looking forward to a post-pandemic world. As we transition back to something closer to normal life, however, the importance of rapid detection of any pathogen that could be hazard...
OraSure is well positioned to capture additional market share in DNA at-home testing and molecular collection device sales. The company offers differentiated propositions with unique exposure to the genome, microbiome and Covid-19 testing. Sequential growth patterns quarter/quarte...
Co-Diagnostics is well positioned to benefit from incremental fundamental momentum seen at the back end of 2020. The company's Covid-19 tests are differentiated by distinguishing between common cold and SARS-CoV-2 with an easy to use platform. Given the epidemiology of the common ...
Are These The Top Biotech Stocks To Watch Now? 3 To Consider Biotech stocks are still amongst the top performers on the stock market as we started off 2021. With numerous life-threatening diseases still running amok, there is a grave need for the treatments these companies d...
News, Short Squeeze, Breakout and More Instantly...
Co-Diagnostics, Inc. to Host Booth and Discuss Advancing POC/OTC Diagnostics at ADLM 2024 in Chicago PR Newswire SALT LAKE CITY , July 29, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company wi...
Co-Diagnostics, Inc. Announces Second Quarter 2024 Earnings Release Date and Webcast PR Newswire SALT LAKE CITY , July 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the developme...
Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers across 15 U.S. States PR Newswire SALT LAKE CITY , July 2, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx™"), a molecular diagnostics company w...